Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Malcolm Ethridge from Capital Area Planning Group sees potential in ServiceNow, Inc. despite recent dip. Bristol-Myers and ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Bristol Myers Squibb recorded a one-time charge of $12.1 billion for the acquisition of Karuna in Q1’24, and expects its full-year earnings to fall to $0.75 per share at the mid-point of the ...

We expect Bristol Myers Squibb’s earnings to plunge to $0.76 in per share in 2024, versus $7.51 last year. However, this figure is expected to rebound to $7.30 in 2025.

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...

Bristol Myers Squibb (NYSE: BMY) is a big name in healthcare. And over the years, it has always found ways to grow and expand its business. But this hasn't been a good buy of late. It's not just ...

Bristol Myers Squibb appointed Nathan Pennell, MD, PhD, FASCO, as SVP, worldwide head of medical affairs for hematology and oncology, effective August 18. Nucleus RadioPharma hired former Food and ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.